Literature DB >> 25068305

Methane intestinal production and poor metabolic control in type I diabetes complicated by autonomic neuropathy.

V Cesario1, T A Di Rienzo, M Campanale, G D'angelo, F Barbaro, G Gigante, G Vitale, G Scavone, D Pitocco, A Gasbarrini, V Ojetti.   

Abstract

AIM: At the state of art it's unknown the correlation between diabetes and lower gastrointestinal disorders. Some studies show a significantly higher prevalence of small intestinal bacterial overgrowth in patients with type I diabetes in particular complicated by autonomic neuropathy. No data exists about gastrointestinal methane production in patients with diabetes and autonomic diabetic neuropathy. The aim of this paper was to evaluate the correlation of small intestinal bacterial overgrowth and gastrointestinal methane production with metabolic control and daily insulin requirements in patients with type 1 diabetes and. autonomic diabetic neuropathy.
METHODS: Thirty subjects with type 1 diabetes and autonomic diabetic neuropathy were underwent hydrogen and methane lactulose breath test (LBT) to evaluate the presence of small intestinal bacterial overgrowth (double peak of hydrogen) and methane production. The metabolic control was evaluated through the glycated hemoglobin and the daily insulin requirement (calculated as ratio between total insulin units in a day and body weight). Methane producers were treated with metronidazole (500 mg bid for 10 days) and perform a LBT 8 weeks after the end of therapy
RESULTS: Eight over thirty patients (26.6%) met the diagnostic criteria for small intestinal bacterial overgrowth. 11/30 patients (36%) were methane-producers (mean baseline value 16.37 ± 13.01 ppm; mean peak 26.62 ± 11.41 ppm); interestingly this subset of patients showed a worse glycemic control (mean HbA1c 8.16 ± 0.9% vs. 7.49 ± 0.8%, P<0.05). After metronidazole therapy 7/11 (63.3%) reduced CH4 production and they showed a mean HbA1c significantly lower than corresponding value before antibiotic therapy (7.63 ± 0.7% vs. 8.25 ± 0.8%).
CONCLUSION: Our study showed for the first time a possible role of CH4 production in metabolic control. In particular, the most interesting data is that an increased values of HbA1c seems to be related to a gut CH4 production as confirmed by its significant improvement after eradication therapy. We are not yet able to determine whether poor glycemic control is the cause or the consequence of the selection of methanogenic flora.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25068305

Source DB:  PubMed          Journal:  Minerva Endocrinol        ISSN: 0391-1977            Impact factor:   2.184


  6 in total

Review 1.  Diabetes-related dysfunction of the small intestine and the colon: focus on motility.

Authors:  Viktor József Horváth; Zsuzsanna Putz; Ferenc Izbéki; Anna Erzsébet Körei; László Gerő; Csaba Lengyel; Péter Kempler; Tamás Várkonyi
Journal:  Curr Diab Rep       Date:  2015-11       Impact factor: 4.810

2.  Type 1 diabetic patients with peripheral neuropathy have pan-enteric prolongation of gastrointestinal transit times and an altered caecal pH profile.

Authors:  Adam D Farmer; Anne Grave Pedersen; Birgitte Brock; Poul Erik Jakobsen; Jesper Karmisholt; Sahar D Mohammed; S Mark Scott; Asbjørn Mohr Drewes; Christina Brock
Journal:  Diabetologia       Date:  2017-01-20       Impact factor: 10.122

3.  Metabolic effects of eradicating breath methane using antibiotics in prediabetic subjects with obesity.

Authors:  Ruchi Mathur; Kathleen S Chua; Mindy Mamelak; Walter Morales; Gillian M Barlow; Rita Thomas; Darko Stefanovski; Stacy Weitsman; Zachary Marsh; Richard N Bergman; Mark Pimentel
Journal:  Obesity (Silver Spring)       Date:  2016-02-01       Impact factor: 5.002

4.  Breath methane concentrations and markers of obesity in patients with functional gastrointestinal disorders.

Authors:  Clive H Wilder-Smith; Søren S Olesen; Andrea Materna; Asbjørn M Drewes
Journal:  United European Gastroenterol J       Date:  2017-11-15       Impact factor: 4.623

5.  The Fecal Microbiota Is Already Altered in Normoglycemic Individuals Who Go on to Have Type 2 Diabetes.

Authors:  Li Wang; Xinwen Yu; Xiaoqiang Xu; Jie Ming; Zhifeng Wang; Bin Gao; Ying Xing; Jie Zhou; Jianfang Fu; Tao Liu; Xiangyang Liu; Malgorzata A Garstka; Xiaokai Wang; Qiuhe Ji
Journal:  Front Cell Infect Microbiol       Date:  2021-02-18       Impact factor: 5.293

6.  Astaxanthin n-Octanoic Acid Diester Ameliorates Insulin Resistance and Modulates Gut Microbiota in High-Fat and High-Sucrose Diet-Fed Mice.

Authors:  Yuan Gao; Lu Yang; Yaoxian Chin; Fang Liu; Robert W Li; Shihan Yuan; Changhu Xue; Jie Xu; Qingjuan Tang
Journal:  Int J Mol Sci       Date:  2020-03-20       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.